Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28691524 | 1.00 | LMNA (0.42) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL27989892 | 1.00 | LMNA (0.42) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL3676122 | 1.00 | LMNA (0.42) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL7902914 | 1.00 | LMNA (0.42) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL3723747 | 1.00 | LMNA (0.42) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL2458373 | 1.00 | LMNA (0.42) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL29055449 | 1.00 | LMNA (0.42) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL3579746 | 1.00 | LMNA (0.42) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL3679045 | 0.96 | SMN1; SMN2 (0.39) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| Ethylene SCHEMBL7913495 | 0.94 | LMNA (0.38) | LMNAALDH1A1TSHRHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170080095-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | APOSENSE LTD. (IL) | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170080095-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | ABCB4, LNPK, MBOAT1 | LMNA 232/4885ALDH1A1 3993/4885TSHR 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.